New Fixed-Dose Subcutaneous Option for HER2+ Breast Cancer

New Fixed-Dose Subcutaneous Option for HER2+ Breast Cancer

Episodes

Specialty:

All

Year:

All

EP. 1: Historic Perspectives on HER2+ Breast Cancer

ByMark Pegram, MD, Stanford Women's Cancer Center,Chau Dang, MD, Memorial Sloan Kettering Westchester,Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

September 24th 2020

EP. 2: Dual HER2-Targeted Approaches in Breast Cancer

ByMark Pegram, MD, Stanford Women's Cancer Center,Chau Dang, MD, Memorial Sloan Kettering Westchester,Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

September 24th 2020

EP. 3: Administration of Dual HER2-Targeted Therapy in BC

ByMark Pegram, MD, Stanford Women's Cancer Center,Chau Dang, MD, Memorial Sloan Kettering Westchester,Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

September 24th 2020

EP. 4: Efficacy of Fixed-Dose Subcutaneous Therapy for HER2+ BC

ByMark Pegram, MD, Stanford Women's Cancer Center,Chau Dang, MD, Memorial Sloan Kettering Westchester,Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

September 24th 2020

EP. 5: Clinical Outcomes in HER2+ BC: FeDeriCa and PHranceSCa

ByMark Pegram, MD, Stanford Women's Cancer Center,Chau Dang, MD, Memorial Sloan Kettering Westchester,Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

September 24th 2020

EP. 6: The Impact of Subcutaneous Option for HER2+ BC

ByMark Pegram, MD, Stanford Women's Cancer Center,Chau Dang, MD, Memorial Sloan Kettering Westchester,Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

September 24th 2020

EP. 7: Q&A: Practical Considerations in HER2+ Breast Cancer

ByMark Pegram, MD, Stanford Women's Cancer Center,Chau Dang, MD, Memorial Sloan Kettering Westchester,Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

September 24th 2020

Trending on OncLive

Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer

Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape

Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial

QTX3034 Plus Cetuximab Receives FDA Fast Track Designation in KRAS G12D–Mutated CRC

FDA Grants Fast Track Designation to MC001 in Pancreatic Cancer